Skip to main content
ereHEALTH

How TMS Works for Depression

TMS targets the left dorsolateral prefrontal cortex (DLPFC), a brain region involved in mood regulation that is consistently underactive in patients with depression. Focused magnetic pulses stimulate this area, increasing neural activity in circuits that medication may not effectively reach.

Standard Protocols

Daily sessions delivered over 4 to 6 weeks. This is the most extensively studied approach and is typically covered by insurance when treatment-resistant criteria are met.

Accelerated Protocols

Compressed treatment timelines using theta burst stimulation or multiple daily sessions, delivering the full treatment course in a shorter period.

One-Day Accelerated Protocol

The entire treatment course delivered in a single day. This is our most time-efficient and cost-effective option.

The protocol decision is made during your consultation with Dr. Nazarani based on your clinical picture, treatment history, and practical needs.

Who Is a Candidate?

You have tried medication without adequate results.

This is the most common pathway to TMS for depression. If one or more antidepressants have not provided sufficient improvement, or if side effects have made medication difficult to tolerate, TMS is a clinically supported next step. Insurance typically covers standard TMS protocols for depression when treatment-resistant criteria are met.

You prefer a non-medication approach.

Some patients want to pursue TMS before trying medication, or instead of medication entirely. This is a valid clinical choice, available as a self-pay option.

TMS for depression is not appropriate for patients with metal implants in or near the head, a history of seizures, or certain neurological conditions. Candidacy is evaluated during your consultation.

What the Research Shows

Depression has the most robust evidence base of any condition treated with TMS. The data below summarizes outcomes across standard and accelerated protocols.

Standard Protocols

In large clinical studies, approximately 50–60% of patients with treatment-resistant depression respond to a standard TMS protocol, and approximately 30–35% achieve full remission. Among those who respond, roughly 60–65% maintain their improvement at 12 months.

Accelerated Protocols

Newer accelerated protocols have demonstrated substantially higher outcomes in early research. The Stanford SAINT trial, a randomized controlled trial of 5-day accelerated TMS, reported a 79% remission rate in patients with severe treatment-resistant depression.

One-Day Accelerated Protocol

A single-day accelerated protocol (ONE-D) has reported response rates of approximately 80–90% and remission rates of 56–75% by 6 weeks, with results sustained through 12 weeks. These findings come from an initial 32-patient open-label case series. A larger propensity-matched comparison of 106 single-day patients versus 191 standard-protocol patients found approximately 50% remission with the single-day approach compared to approximately 25% with standard treatment at 6 weeks. No randomized controlled trial of single-day TMS has been completed, and larger studies are underway.

For Context

In the landmark STAR*D trial, the largest study of antidepressant medication, approximately one-third of patients achieved remission with their first medication. By the fourth medication trial, remission rates dropped below 10%.

Not everyone responds to TMS. Individual results vary, and Dr. Nazarani will discuss realistic expectations during your consultation.

Sources: Carpenter et al. (2012), Dunner et al. (2014), Cole et al. (2022), Vaughn et al. (2025), Berlow et al. (preprint), Rush et al. (2006).

What else you should know

This page covers TMS for depression specifically. For details on how TMS treatment works, what sessions feel like, and cost and insurance information, see our TMS Overview.

Frequently Asked Questions

Yes. Treatment-resistant depression is one of the primary indications for TMS. It works through a different mechanism than medication, targeting brain circuits directly rather than altering neurochemistry systemically.

In most cases, yes. Dr. Nazarani reviews your current medications during the evaluation and advises on any adjustments needed before or during treatment.

Among patients who respond to standard TMS, roughly 60–65% maintain their improvement at 12 months. Some patients benefit from periodic maintenance sessions. Durability varies by individual and protocol.

Early research suggests comparable or higher outcomes with accelerated single-day protocols, though the evidence base is newer and based on smaller studies. The One-Day Protocol is the most time-efficient and cost-effective option. Dr. Nazarani can help you determine which protocol is the best fit.

Find Out If TMS for Depression Is Right for You

The first step is a consultation with Dr. Nazarani to evaluate whether TMS is appropriate for your situation and which protocol fits best. You are not committing to treatment — you are finding out if it makes sense for you.